<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028521</url>
  </required_header>
  <id_info>
    <org_study_id>CellMed CM3.1-AC100/01</org_study_id>
    <secondary_id>EudraCT No. 2009-017344-13</secondary_id>
    <nct_id>NCT01028521</nct_id>
  </id_info>
  <brief_title>First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100</brief_title>
  <official_title>Single-centre, Randomised, Double-blind, Placebo-controlled Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellMed AG, a subsidiary of BTG plc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellMed AG, a subsidiary of BTG plc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first time in man, phase I study to assess the safety, tolerability and pharmacokinetics of
      single ascending doses of CM3.1-AC100 in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measurements (Adverse events, ECG recordings, blood pressure, pulse, body temperature, laboratory variables,local tolerability, nausea questionnaire)</measure>
    <time_frame>Safety will be monitored continously and safety assessments will be made on several occasions throughout the whole study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CM3.1-AC100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CM3.1-AC100</intervention_name>
    <description>Solution for sc injection, single ascending doses</description>
    <arm_group_label>CM3.1-AC100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for sc injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated informed consent prior to any study specific procedures

          -  Body weight between 60.0 to 100.0 kg (both inclusive) and BMI 19 to 29.9 kg/m2 (both
             inclusive)

          -  Judged as healthy by a comprehensive clinical assessment (detailed medical history and
             complete physical examination)

        Exclusion Criteria:

          -  Any history or presence of a clinically relevant disease as judged to be relevant by
             the Investigator

          -  Blood donation within 3 month before administration of the IP

          -  Have a history of hypersensitivity to the IP or any of the excipients or to medicinal
             products with similar chemical structures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Geigle, Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>CellMed AG, a subsidiary of BTG plc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>July 14, 2010</last_update_submitted>
  <last_update_submitted_qc>July 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Peter Geigle</name_title>
    <organization>Cellmed AG</organization>
  </responsible_party>
  <keyword>First time in man, safety study, Cm3.1-AC100</keyword>
  <keyword>Male volunteer aged 18 to 50 years at Screening</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

